ARTICLE | Clinical News
Elagolix: Phase IIb completed
June 23, 2008 7:00 AM UTC
Neurocrine completed the 6-month treatment stage of the double-blind, Phase IIb Petal trial in 252 patients comparing elagolix vs. Depo-Provera from Pfizer Inc. (NYSE:PFE, New York, N.Y.). ...